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Abstract:
 
Hematide
 
TM
 
 is a synthetic peptide-based, PEGylated erythropoiesis-stimulating agent, which is being developed
for the chronic treatment of anaemia associated with chronic renal failure. To support the safety of long-term dosing of chronic
renal failure patients, a comprehensive toxicology programme was implemented including rat subchronic and chronic studies.
Rats were administered 0, 0.1, 1 and 10 mg/kg of Hematide every 3 weeks for 3 months via subcutaneous injection or for
6 months via intravenous injection. The dosing period was followed by a 6-week follow-up period. The primary pharmacology
of Hematide resulted in erythroid polycythemia as measured by elevated haemoglobin levels that were time- and dose-
dependent. The pharmacology proﬁles were similar regardless of administration route. For example, for male rats at Day
90, subcutaneous dosing resulted in haemoglobin increases of 2.7, 4.5 and 6.9 g/dl for 0.1, 1 and 10 mg Hematide/kg
respectively, compared to 2.8, 5.7 and 7.4 g/dl increases for intravenous dosing. Histopathological changes were related to
the prolonged severe polycythemia induced in normocythemic animals administered an erythropoiesis-stimulating agent.
The ﬁndings included extramedullary haematopoiesis in the spleen and liver, bone marrow hypercellularity and organ
congestion. Microscopic ﬁndings were reversible, demonstrating a return towards control ﬁndings within 6 weeks following
cessation of dosing. Systemic exposures, based on both area under the curve (AUC) and maximum concentration (C
 
max
 
), were
substantially greater for intravenous than subcutaneous administration. No Hematide-speciﬁc antibodies were detected. In
conclusion, Hematide is a potent erythropoiesis-stimulating agent, and the studies provide support for the safety of clinical
 
development, including chronic dosing, for the treatment of anaemia associated with chronic renal failure.
 
Anaemia in patients with chronic renal failure, which is caused
primarily by an inadequate production of erythropoietin by the
 
damaged kidneys [1], results in a reduction in length and quality
of the patient’s life [2]. The treatment of anaemia associated
with kidney disease has been successfully carried out on more
than a million patients by the use of recombinant human
erythropoietin proteins [3]. However, the short half-life and
pharmacological action of the currently available recombinant
products, their potential to cause antibodies against endogenous
erythropoietin and related analogues, high cost and lack of
room temperature stability provide development incentives.
Hematide
 
TM
 
 is a synthetic peptide-based, PEGylated
erythropoiesis-stimulating agent. The molecule was designed
to bind and activate the erythropoietin receptor, stimulating
red blood cell production [4]. PEGylation generally results
in an increase in protein/peptide solubility, an increase in
plasma half-life by shielding the molecule from proteolysis
and by reducing renal clearance, and a decrease in immuno-
genicity by masking epitopes [5]. Hematide’s novel primary
amino acid sequence is unrelated to that of human erythro-
poietin. Therefore, any potential antibody formed to Hematide is
not likely to cross-react with erythropoietin and induce pure red
cell aplasia. Hematide’s lack of erythropoietin immunological
cross-reactivity makes it capable of increasing haemoglobin in rats
when their anaemia was caused by anti-erythropoietin anti-
bodies that cross-react with endogenous erythropoietin following
the administration of recombinant human erythropoietin [6].
Most importantly, it has eliminated the need for transfusions
in patients with anti-erythropoietin antibody-mediated pure
red cell aplasia [7].
Hematide is being developed for the treatment of anaemia
secondary to chronic renal failure in a patient population that
requires lifelong therapy. To support chronic clinical therapy,
a series of repeat-dose pharmacodynamic, safety and phar-
macokinetic studies was performed in animals, including
normocythemic rats. Sprague–Dawley rats were studied
after subcutaneous injections of Hematide every 3 weeks for
3 months and after intravenous administration every 3 weeks
for up to 6 months.
 
Materials and Methods
 
All animals received care in compliance with Guide for the Care
and Use of Laboratory Animals (NIH Publication, 1996) and this
study was conducted under the umbrella of an Internal Animal
Care and Use Committee. Sprague–Dawley rats, approximately
8  weeks  old and weighing 148–293  g at the start of dosing, were
obtained from Harlan Sprague Dawley Inc. (Frederick, MD, USA).
The 6-month intravenous study utilized doses of 0, 0.1, 1.0 and
10 mg/kg/dose administered every third week for up to 6 months
for a total of 10 doses (Days 1, 22, 43, 64, 85, 106, 127, 148, 169
and 190). The low dose of 0.1 mg/kg was based, in part, from the
results from the Phase I Hematide healthy volunteer study [8] in
 
Author for correspondence: Kathryn W. Woodburn, Affymax Inc.,
4001 Miranda Avenue, Palo Alto, CA 94304, USA (fax +1
650 424 8312, e-mail kathryn_woodburn@affymax.com).
Re-use of this article is permitted in accordance with the Creative
Commons Deed, Attribution 2.5, which does not permit commer-
cial exploitation. 
156
 
KATHRYN W. WOODBURN
 
 ET AL.
 
© 2008 The Authors
Journal compilation
 
 © 2008 Nordic Pharmacological Society. 
 
Basic & Clinical Pharmacology & Toxicology
 
, 
 
104
 
, 155–163
 
which participants received a single intravenous dose of Hematide
(0.025, 0.05, or 0.1 mg/kg) or placebo. Hematide showed pharma-
cological activity characterized by a statistical increase in reticulocytes
at all doses evaluated and a statistically and biologically signiﬁcant
increase in haemoglobin levels (approximately 1 g/dl) at 0.1 mg/kg
that was sustained for longer than 1 month. Mid-dose of 1 and high
dose of 10 mg/kg are 10 and 100 
 
×
 
 multiples of the pharmacological
active dose from the human healthy volunteer study. The study
design incorporated an interim sacriﬁce on Day 90 (10/sex/group), a
terminal sacriﬁce on Day 195/196 (20/sex/group) and a 6-week
recovery period sacriﬁce on Day 232 (5/sex/group). For the 3-month
subcutaneous study, Hematide was administered at doses of 0, 0.1,
1.0 or 10 mg/kg once every 3 weeks for a total of ﬁve doses (Days 1,
22, 43, 64 and 85). On Day 90 following the dosing period, the animals
(10/sex/group) were killed. The remaining rats (5/sex/group) continued
on study, untreated, following the ﬁnal dose for a 6-week recovery
period, at which time they were killed (Day 126/127). Hematide was
formulated in 10 mM acetate buffered saline (pH 5.5) [4]. Doses were
given as a single bolus 5 ml/kg injection.
A subset of rats for each study was utilized for pharmacokinetic
analysis. Blood was collected from nine animals/sex/group (when
applicable) at 9 time-points (3 per rat) starting on Days 1, 85 and
190 (intravenously only). Plasma drug concentration levels were
determined and pharmacokinetic parameters were calculated.
Mortality and clinical observations were evaluated at least daily.
Subcutaneous injection sites were scored according to Draize [9]. Body
weights and food consumption were recorded weekly. Ophthalmology
examinations were performed before treatment initiation and within
2 weeks prior to scheduled terminations. Upon termination, blood
samples were collected for evaluation of haematology, coagulation
and serum clinical chemistry parameters. Blood for additional
evaluation of haematology was collected on Days 20, 41, 62, 104,
117/118 (subcutaneous), 125 (intravenous), 146 (intravenous), 167
(intravenous), 188 (intravenous) and 218 (intravenous). Urine was
collected overnight for urinalyses on Day 1 and prior to each scheduled
sacriﬁce from animals in Groups 1–4. Analysis of serum for the
presence of anti-Hematide antibody was conducted on blood samples
collected on Days 35, 83, 126/127 (subcutaneous), 195/196 (intravenous)
and 232 (intravenous).
Determination of plasma drug levels and detection of anti-Hematide
antibodies were performed by enzyme-linked immunosorbent assays
(ELISA) as previously described [4,6,8]. Non-compartmental phar-
macokinetic parameters were calculated from plasma concentration–
time proﬁles of Hematide using WinNonlin® software (version 4.1,
Pharsight, Mountain View, CA, USA).
Complete necropsies were performed, tissues were harvested, and
organs were weighed. Due to mortality, primarily at the high dose,
not all of the animals survived to scheduled sacriﬁce on Days 195/
196 or 232. Tissues were harvested at each necropsy and for premature
decedents, organs weighed and tissues evaluated microscopically.
 
Statistical analyses.
 
Data are expressed as mean with standard deviation.
Comparisons of parameters were performed using a one-way
analysis of variance followed by a post-hoc Dunnett’s test. A
P value of <0.05 was considered statistically signiﬁcant.
 
Results
 
In-life evaluations – Hematide-associated effects.
Clinical observations, dermal scoring, body weight, food con-
sumption and ophthalmological evaluation.
 
For the 6-month
intravenous study, the most common clinical observation was
dark pink to red discoloration of the paws and red staining
on the cage paper and/or urogenital area. The ﬁndings were
likely due to the sustained erythropoiesis induced by Hematide
in normocythemic rats. The erythropoietic ﬁndings are
discussed in greater detail in subsequent sections. For the
3-month subcutaneous study, there were generally no test
article-related effects on clinical observations.
There were no test article-related effects on body weight
or food consumption for the 0.1 and 1 mg/kg/dose groups in
the 6-month intravenous study. Increased group body
weight compared to concurrent controls was recorded on
Day 36 and weekly from Days 57 to 169 for the 10 mg/kg/
dose females. The increase in body weight correlated with
an increase in food consumption. Conversely, 10  mg/kg/
dose males had signiﬁcantly decreased group mean body
weight compared to concurrent controls on a weekly basis
from Day 155 to Day 176. However, no signiﬁcant changes
in food consumption were observed. For the subcutaneous
3-month study, there were no test article-related effects on
either body weight or food consumption.
For the intravenous study, there were no test article-
related ophthalmological ﬁndings during the ﬁrst 3 months,
which is consistent with ophthalmological evaluations in rats
dosed with Hematide by subcutaneous injection. A reversible
trend observed during ophthalmic examination of the rats
included an increase in vascular perfusion/hyperaemia of the
choroidal and retinal vasculature across all groups, including
controls, with increased severity in the mid- and high-dose
animals.
 
Haematology, serum chemistry and urinalyses.
 
Regardless of
the route of administration (i.e. intravenous versus subcuta-
neous), Hematide administration resulted in erythropoiesis,
which led to pronounced and sustained polycythemia at the
1 and 10 mg/kg doses. The effect of intravenous Hematide
administration every 3 weeks for 6 months on haemoglobin
levels in normocythemic male rats is depicted in ﬁg. 1.
Fig. 1. Dose- and time-dependent increases in haemoglobin (Hgb)
after intravenous administration. Male rats received vehicle ( ), 0.1
( ), 1.0 ( ) or 10  ( ) mg Hematide/kg/dose every 3  weeks for
6  months. Data are expressed as mean  ±  standard deviation with
arrowheads denoting days of injection. For 0 through 1 mg/kg, 10 rats
were sampled per dose per time-point through Day 188, Day 195
represented 18–20 animals while the remaining time-points represented
5 animals. Six to 10 rats were sampled per dose group for each time-
point for the 10 mg/kg group. 
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In addition, the ﬁgure delineates the time-course for the
reversibility of the Hematide-induced haemoglobin increases
following the 6-week recovery period. By Day  125, the
haemoglobin levels in the 0.1, 1, and 10 mg/kg groups were
18.9 ± 0.73, 22.9 ± 0.75, and 25.4 ± 1.40 g/dl, which reﬂect a
increase of 1.6, 5.6, and 8.1 g Hgb/dl, respectively, over the
concurrent vehicle control group (17.3 g/dl). The changes in
haematology had reversed following cessation of treatment
(Day 190).
Comparable pharmacological responses, with respect to
haematopoiesis, were observed when Hematide was adminis-
tered to rats via the subcutaneous or intravenous routes
every 3 weeks for a total of ﬁve injections. Following adminis-
tration of Hematide, there was a dose-dependent increase
in haemoglobin level, the magnitude of which was similar
between intravenous and subcutaneous administration at
each respective dose level and for each respective time-point
evaluated. Day  90 haemoglobin values in male rats are
representative of the comparability in the pharmacological
response for intravenous and subcutaneous administration
of Hematide. Subcutaneous dosing resulted in haemoglobin
increases of 2.7, 4.5 and 6.9 g/dl over concurrent controls
for 0.1, 1 and 10 mg Hematide/kg, respectively, compared to
2.8, 5.7 and 7.4 g/dl increases, respectively, for intravenous
dosing. Figure 2 illustrates the temporal relationship between
haemoglobin increases and duration of dosing and number
of doses following intravenous and subcutaneous Hematide
administration.
The effect of Hematide on haemotocrit and red blood
cells indices in female rats after intravenous administration
every 3 weeks for 6 months is displayed in ﬁg. 3. Changes
were seen in all groups, but effects were most striking in the
high-dose group (10  mg/kg). The changes are consistent
with those observed in the male rats after intravenous dosing
and in male and female rats after subcutaneous dosing.
Hematide (intravenously and subcutaneously) also induced
alterations in secondary haematological indices (mean
corpuscular volume, mean corpuscular haemoglobin, mean
corpuscular haemoglobin concentration) as well as red blood
cell morphology (anisocytosis, polychromasia, macrocytosis)
that were consistent with polycythemia. The high-dose groups
produced smaller red blood cells (i.e. resulting in a decreased
mean corpuscular volume), which contained less haemoglobin
and haemoglobin concentration (i.e. resulting in a decreased
mean corpuscular haemoglobin and mean corpuscular
haemoglobin concentration, respectively). In contrast, the
low (0.1 mg/kg) and mid-dose (1.0 mg/kg) groups produced
larger red blood cells (mean corpuscular volume) with slightly
more total haemoglobin per cell (mean corpuscular haemo-
globin) but generally the same haemoglobin concentration
(mean corpuscular haemoglobin concentration) as the con-
current vehicle control group. Haematological effects were
similar to controls 6 weeks after cessation of dosing.
Consistent with the stimulation of the red blood cell
precursors and as expected for an erythropoiesis-stimulating
agent, intravenous and subcutaneous Hematide induced reticu-
locytosis. The observed drug-induced changes on reticulocyte
numbers were dependent upon sampling time in relationship
to when the animals were dosed. Figure 4 depicts the changes
in reticulocytes after intravenous administration. When blood
samples were collected approximately 5–6 days after dose
administration (terminal necropsies on Days  90 and 195/
196), reticulocytes were signiﬁcantly increased from controls
at all Hematide dose levels. A compensatory decrease in
reticulocytes, however, was observed when blood samples
were collected approximately 3 weeks after dose adminis-
tration. Reticulocyte numbers were typically less than control
values 3 weeks after dosing, apparently in response to the
increase in red blood cell numbers. Return of reticulocytes
numbers towards vehicle-control values was observed
following a 6-week recovery period in the groups administered
0.1 mg Hematide/kg, while rats at 1.0 mg Hematide/kg remained
slightly decreased compared to concurrent controls in both
sexes.
A synchronicity with dosing, similar to that noted for
reticulocytes, was also observed with platelet levels in rats
administered Hematide by intravenous (ﬁg. 4) or subcutaneous
injection. An increase in platelets was observed soon after
dosing followed by a compensatory decrease approximately
3 weeks after dosing. The changes were related to Hematide
administration; however, they were not of a magnitude
considered to be toxicologically adverse and are conjectured
to be related to an effect on megakaryocytes and/or precursors
[10,11], or functional iron deﬁciency following accelerated
reticulocytosis when high doses of erythropoiesis-stimulating
agents are administered to normocythemic animals [12].
Alterations in serum chemistry were generally considered
to be secondary to the exaggerated pharmacology of Hematide
with ﬁndings being reversed after the 6-week recovery
Fig. 2. Comparable pharmacological response after intravenous and
subcutaneous administration. Generation of mean haemoglobin
(Hgb) ± standard deviation after intravenous (closed symbols) and
(open symbols) subcutaneous administration every 3 weeks to male
rats. Animals were dosed with vehicle (circles), 0.1 (squares), 1.0
(triangles), or 10 (diamonds) mg/kg. Arrows denote administration
days. Each point represents the mean of 9–10 animals through Day 90
and 5–10 animals for Day 104. 
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periods. Hematide-associated changes were generally similar
after intravenous or subcutaneous dose administration. The
alterations in serum chemistry included increases in bilirubin
and aspartate aminotransferase and an initial decrease and
subsequent increase in serum iron. Small increases, deemed
toxicologically insigniﬁcant, in creatinine levels were observed
at Day 195 in the mid- and high-dose groups (0.5 ± 0.09 mg/dl
for 10 mg/kg males compared to 0.4 ± 0.02 mg/dl for con-
current controls; 0.6 ± 0.16 mg/dl for 10 mg/kg females com-
pared to 0.5 ± 0.05 mg/dl for concurrent controls, P < 0.05).
The changes in bilirubin and serum iron are depicted in
ﬁg. 5, and are considered to be secondary sequelae to the
marked increases in red blood cells and haemotocrit. The
increases in bilirubin and aspartate aminotransferase are
likely due to increased erythrocyte turnover secondary to
accelerated erythropoiesis and/or red blood cell haemolysis.
The initial serum iron depletion on Days 90 and 195 is likely
the result of incorporation into haemoglobin during rapid
erythrocyte production (e.g. a functional iron deﬁciency).
By Day  232, total serum iron was increased, which likely
reﬂects the release of iron during erythrocyte breakdown
secondary to signiﬁcant polycythemia.
Urinalyses evaluation showed there were no differences in
urine pH or speciﬁc gravity after approximately 3 months of
treatment. On Day 90, there was an increase in urine protein
compared to concurrent controls for male rats treated with
 
≥
 
1.0 mg Hematide/kg after intravenous administration and
for female rats receiving subcutaneous administration. On
Day 126/127, three of ﬁve females dosed at 10 mg Hematide/kg
subcutaneously had notably increased urine protein com-
pared to controls. On Day 195/196, there were signiﬁcantly
decreased group urine pH values compared to concurrent
controls for male rats intravenously dosed at 
 
≥
 
1.0 mg
Hematide/kg. The changes in urine protein correlated with
the renal glomerular and tubular lesions. There were no
clear test article-related effects on qualitative or quantitative
urinalysis parameters noted after a 6-week recovery.
Prothrombin time was signiﬁcantly increased from controls
in both the high-dose intravnous and subcutaneous males at
Day 90. Activated partial thromboplastin time was increased
in the high-dose animals at Day 90. By Day 195/196 of the
intravenous toxicity study, both prothrombin time and
activated partial thromboplastin time were signiﬁcantly
increased from controls for rats at dose levels equal to or
Fig. 3. Hematide induces signiﬁcant changes in haematocrit (Hct) and secondary haematologic indices. Alterations in Hct, mean corpuscular
volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC) were assessed after
intravenous administration of vehicle ( ), 0.1 ( ), 1.0 ( ) or 10 ( ) mg Hematide/kg every 3 weeks to female rats for 6 months. Mean
data ± standard deviation is presented with arrows denoting days of administration. For 0 through 1 mg/kg, 9 to 10 rats were sampled per
dose per time-point through Days 188, Day 195 represented 19–20 animals while the remaining time-points represented 4–5 animals. Five to
10 rats were sampled per dose group for each time-point for the 10 mg/kg group. The spikes on Days 85 and 195 are related to samples taken
soon after dosing (5 days) compared to the other time-points which were generally taken 2 days preceding dosing. 
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greater than 1.0 mg Hematide/kg, except for the high-dose
males. Although not attaining signiﬁcance, the prothrombin
time and activated partial thromboplastin time in the high-
dose males were, however, notably increased. The observed
increases in coagulation parameters were most likely spurious
because similar false prolongations due to method interference
have been reported in samples with high haematocrits [13].
 
Mortality.
 
The physiological perturbations secondary to the
sustained and profound polycythaemia that occurs when an
erythropoiesis-stimulating agent is administered to normo-
cythemic rats was considered to be the cause of death and
unscheduled moribund sacriﬁces in the rats administered
Hematide by either intravenous or subcutaneous injection.
Premature deaths that were considered to be test article-
related occurred in one mid-dose male rat (1.0 mg/kg; Day 50)
from the 3-month subcutaneous study and 40 high-dose
(10 mg/kg) and 2 mid-dose rats (1 mg/kg) from the 6-month
intravenous study. Figure 6 illustrates the correlation between
the incidence of mortality and the magnitude of haemoglobin
increase and the dosing duration (i.e. duration of persistent
polycythemia). The magnitude of the increase in haemo-
globin associated with repeat dosing of Hematide exhibited
a relatively sharp dose–response curve and appeared to
plateau. The maximum increase in haemoglobin appeared
to be approximately 7–9 g/dl. Mortality, which was greater
in the intravenous versus subcutaneous study, was noted
primarily after Day 90 of the study. The difference in mor-
tality rate between the two studies, therefore, may in part
reﬂect differences in the duration of the study (i.e. 90 versus
195/196 days for the subcutaneous versus intravenous study).
In general, mortality was observed with the persistence of
haemoglobin levels greater than approximately 23–24  g/dl
for more than 90 days.
 
Immunogenicity.
 
Antibodies to Hematide were not observed
in any of the samples collected from the intravenous and
subcutaneous studies.
 
Pharmacokinetics.
 
Hematide exhibited persistence in the plasma
following either intravenous or subcutaneous administration.
With the exception of the 10 mg/kg subcutaneous dose on
Day 1, the half-life of Hematide was generally similar after
subcutaneous and intravenous administration at a given
dose level. Half-life values ranged from 13.9 to 26.1 hr for
doses of 0.1 and 1.0 mg/kg and, excluding the 10 mg/kg
Fig. 4. Reticulocyte and platelet proﬁles in female (left) and male rats (right) after intravenous administration of vehicle ( ), 0.1 ( ), 1.0 ( )
or 10 ( ) mg Hematide/kg every 3 weeks for 10 administrations followed by a 6-week recovery. Data are represented as mean values ±
standard deviation. Arrows denote days of administration. For 0 through 1 mg/kg, 8 to 10 rats were sampled per dose per time-point through
Days 188, Day 195 represented 18–20 animals while the remaining time-points represented 4–5 animals. Five to 10 rats were sampled per dose
group for each time-point for the 10 mg/kg group. Results show a synchronicity with dosing; when sampling times occurred soon after dosing
(Days 90 and 195/196, 5 days after administration) elevations in parameters are observed. 
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subcutaneous dose on Day 1, ranged from 29.7 to 40.6 hr
at 10  mg/kg. Selected pharmacokinetic parameters are
summarized in table 1.
As anticipated, systemic exposures, based on both C
 
max
 
and AUC, were substantially greater for intravenous versus
subcutaneous routes of administration. After intravenous
administration, C
 
max 
 
was generally observed at the ﬁrst
sampling time (1 hr), but C
 
max
 
 after subcutaneous adminis-
tration was within 24 to 48 hr after dosing (data not shown).
Increases of C
 
max
 
 and exposure (AUC) values were greater
than dose proportional across all dose levels and at all
dosing intervals.
With intravenous administration, there were no remarkable
gender-related differences in the pharmacokinetic parameters.
On Day 85, gender differences were apparent after subcu-
taneous dosing, with C
 
max
 
 and AUC values twofold higher
in females relative to males. Since the elimination half-life
was not different between males and females, the gender-
related exposure was suggestive of a difference in the extent
of absorption after subcutaneous dosing. The subcutaneous
bioavailability estimated at 1 mg/kg dose was 22.7% for males,
and 43.4% for females.
In the 6-month intravenous study, there were no remarkable
changes in pharmacokinetics at the low dose throughout the
6-month dosing period. A slight accumulation was apparent
at the higher doses, which is considered likely to reﬂect
the reduced plasma volumes secondary to haemoconcentra-
tion. No accumulation was observed at any dose after sub-
cutaneous administration of Hematide every 3 weeks for
3 months.
 
Post-mortem evaluations – Hematide-associated effects.
Gross ﬁndings and organ weights.
 
The most common test article-
related gross ﬁndings were enlarged spleens and organ con-
gestion. Organ congestion and/or increased erythropoiesis
appeared to translate into an increase in mean organ weights
for several organs including the liver and spleen. Injection
site alterations were minimal and were not associated with
any test article-related microscopic changes.
 
Histopathology.
 
Histopathological changes observed in both
the intravenous and subcutaneous studies were due to the
primary pharmacological effects of Hematide and secondary
sequelae.  Primary pharmacological responses observed at
Fig. 5. Iron and bilirubin proﬁles are consistent with accelerated erythropoiesis, polycythemia, increased red blood cell (RBC) turnover and
subsequent recovery. Mean values ± standard deviation after intravenous administration of vehicle every 3 weeks ( ), 0.1 ( ), 1.0 ( ) or
10 ( ) mg Hematide/kg to male rats for 6 months followed by a 6-week recovery. Arrows denote day of administration. Data for RBCs and
haemotocrit (Hct) were obtained from the same animals represented in ﬁg. 1. For Fe and bilirubin (TBili) determination, 0 through 1 mg/kg,
10 rats were sampled on Day 1, 9 to 10 on Day 90, 18 to 20 on Day 195 and 5 on Day 232. For the 10 mg/kg groups, 10 animals were sampled
on Day 1, 1 on Day 90 and 7 on Day 195. 
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scheduled necropsies (Days 90, 195/196) were indicative of
increased red cell production and included hypercellularity
of femoral bone marrow, increased erythropoiesis in the
sternal bone marrow, extramedullary erythropoiesis in the
spleen and liver, and congestion occurred in all Hematide
treatment groups with dose-related severity. Such patterns
were not observed following the 6-week recovery period.
Histopathological ﬁndings considered secondary to
drug-induced haemodynamic changes included thrombosis
and infarction in multiple organs primarily in the mid- and
high-dose groups. In addition, cardiac changes, including
thrombosis, stromal proliferation of the valves, myocardium
or endocardium, and myocardial degeneration, were common
in rats found dead and sacriﬁced moribund.
There were several ﬁndings in the rat that have been
described as age-related spontaneous lesions, and appear to
have been exacerbated by Hematide-related haemodynamic
changes. The age-related spontaneous changes included
chronic progressive nephropathy and/or tubular regeneration
as well as periarteritis [14,15]. The periarteritis was considered
likely related to altered haemodynamic patterns secondary
to an increase in blood viscosity and haemoconcentration
and was observed primarily in the high-dose group at the
3-month interim sacriﬁce and in the mid- and high-dose
groups at 6 months. Haemodynamic alterations due to test
article-induced polycythemia and haemoconcentration have
been reported for other approved erythropoiesis-stimulating
agents. The renal ﬁndings were attributed to altered renal
perfusion secondary to Hematide-induced haemodynamic
disturbances and/or the known renal toxic effects of excess
haemoglobin (e.g. haemoglobin crystals and casts). Based
on the severity of the renal changes, they are generally not
anticipated to result in any signiﬁcant functional perturbation.
 
Discussion
 
Hematide is a potent erythropoiesis-stimulating agent,
producing dose- and time-dependent increases in erythro-
poiesis. Unlike currently approved erythropoiesis-stimulating
agent, no neutralizing antibodies were produced in the rodent
studies, thereby allowing the ﬁrst examination of the effects
of chronic and severe polycythemia in normocythemic
animals associated with administration of an erythropoiesis-
stimulating agent.
The haematological and serum chemistry changes observed
with Hematide, regardless of the route of administration
(e.g. intravenous or subcutaneous) were anticipated based
on the pharmacology of the drug. In addition, the test article-
related effects noted, from discoloration of tissues, widespread
congestion, organ weight changes, renal tubular morphological
and functional alterations, thromboses with resultant ischaemic
tissue damage and mortality, occurred in direct response
to the pronounced erythropoiesis induced by Hematide’s
pharmacology in a normocythemic animal model. There
were no tissue lesions that were considered to be related
to a direct toxicity of Hematide. In surviving animals, the
discontinuation of dosing led to recovery from the haemato-
logical and associated systemic effects and at least partial
recovery for microscopic changes. The nature of the changes
observed microscopically by the end of the recovery period
is consistent with a full recovery over time.
As expected, the exposure based on C
 
max
 
 and AUC was
substantively greater at comparable doses after intravenous
versus subcutaneous administration. However, the ﬁndings
(pharmacology and safety) in the subcutaneous rat study
were similar to those from the intravenous studies. Further-
more, anti-Hematide antibody analysis after repeated dosing
with Hematide by either the intravenous or subcutaneous
route of administration did not demonstrate the presence of
Hematide-reactive antibodies in rats that could have potentially
confounded interpretation of the pharmacokinetic data.
 
Conclusion
 
Hematide is presently being evaluated in clinical trials [16]
for the treatment of anaemia associated with chronic renal
failure. Hematide’s clinical pharmacodynamic proﬁle supports
dosing every 3–4 weeks. The studies described herein were
Fig. 6. Relationship between polycythemia and mortality. Temporal
generation of haemoglobin and survival after 6 months of Hematide
dosing in male rats. The temporal generation of haemoglobin (Hgb)
in male rats is shown in the top panel while survival (Days 90 to
190) is shown in the form of a Kaplan–Meier curve in the bottom
panel. Hematide was administered intravenously at 0 ( ), 0.1 ( ),
1.0 ( ) or 10 ( ) mg mg/kg every 3 weeks for a total ten
administrations. 
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performed to support the use of Hematide in the clinical
setting (i.e. chronic dosing). These studies were performed in
healthy, normocythemic animals, with normal haemoglobin
levels before treatment. The toxicological effects observed
after intravenous and subcutaneous administration of Hematide
are considered to be related to the exaggerated pharmacology
and secondary sequelae that result from administration of
an erythropoiesis-stimulating agent to a normocythemic animal.
Chronic non-clinical studies can be conducted with Hematide
without the confounding effects of neutralizing antibodies.
The patient population for which chronic Hematide dosing
is targeted will be anaemic and the intent of Hematide treat-
ment is to return red blood cell parameters towards normal
values. Therefore, the risk that the sequelae observed in the rat
toxicity study, which are considered secondary to exaggerated
pharmacology (e.g. sustained and pronounced polycythemia)
will occur in the intended patient population is notably less.
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